Middle East & Africa Animal and Human Vaccines Market - Industry Trends and Forecast to 2031
The Middle East and Africa animal and human vaccines market is expected to reach USD 5,358,452.8 thousand by 2031 from USD 3,480,103.50 thousand in 2023, growing with a CAGR of 5.6% in the forecast period of 2024 to 2031.
Market SegmentationMiddle East and Africa Animal and Human Vaccines Market, By Type (Human and Animal), End User (Hospital, Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) Country (South Africa, Nigeria, Ethiopia Tanzania Kenya Algeria, Ghana, Mozambique, Uganda, Democratic Republic of Congo, Sudan, Morocco Angola Madagascar Malawi ZambiaIvory Coast, Cameroon, Zimbabwe, Libya, Chad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Comoros, Seychelles, Rest of Africa Saudi Arabia, Egypt, U.A.E., Israel, Iran, Iraq, Oman, Kuwait, Qatar, Bahrain, Yemen, Jordan, Lebanon, Palestine, and Rest of Middle East) - Industry Trends and Forecast to 2031
Overview of the Middle East and Africa Animal and Human Vaccines Market Dynamics
Driver
• Growing immunization programs and campaigns
Restraint
• Unavailability of registered vaccines in the market
Opportunity
• Strategic initiation and decisions taken by the market players
Market PlayersSome of the major market players operating in the Middle East and Africa animal and human vaccines market are: • GSK plc.
• Merck & Co., Inc.
• Sanofi
• Boehringer Ingelheim International GmbH.
• Ceva
• OBP
• M.C.I Santé Animale
• Biogénesis Bagó
• HESTER BIOSCIENCES LIMITED
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.